|
|
| Reliance Pharma Fund (G) |
|
|
|
|
|
|
|
| NAV Details |
| NAV Date : |
22-Feb-12 |
| NAV [Rs] : |
54.46 |
| Buy/Repurchase Price [Rs] : |
53.92 |
| Sell/Resale Price [Rs] : |
54.46 |
| Entry Load % : |
NIL |
| Exit Load % : |
1% if redeemed or switchd out on or efore completion of 1 years from the date of allotment of units.
NIl if redeemed or switched out after the completion of 1 years from the date of allotment of units. |
|
|
|
| Latest Payouts |
| |
Dividends |
Bonus |
| Ratio |
NA |
NA |
| Date |
NA |
NA |
|
|
|
|
| Investment Details |
| Tax Benefits : |
112(1) |
| Min. Investment Rs : |
5000 |
| Increm.Investment Rs : |
1 |
|
|
|
|
|
|
| |
1 Week |
1 Month |
3 Month |
6 Month |
1 Year |
3 Year |
5 Year |
Since INC |
|
|
|
|
|
|
| Statistical Ratios |
What
is Beta ?
Beta is a measure of the volatility of the portfolio to that of the index. In
simple words it shows the movement of the portfolio in comparison. The Higher
the Beta, higher the volatility of the scheme to the index. If its greater
than1 , then the portfolio is highly volatile to the movemnts in the index. If
the beta is lesser than 1 , then scheme is less volatile to the index and beta
which is close to 1 implies that the scheme is closely following the index.
|
| Beta [%] |
SD [%] |
Sharpe Ratio [%] |
Jensons Alpha [%] |
ER [%] |
| 0.7999 |
6.3313 |
0.3832 |
1.1315 |
3.0330 |
|
|
|
|
| Asset Allocation |
|
|
|
|
|
|
|
| Holdings |
31-Jan-12 |
| Company Name |
% Hold |
| Divi's Lab. |
10.85 |
| Aventis Pharma |
8.56 |
| Ranbaxy Labs. |
8.54 |
| Sun Pharma.Inds. |
8.53 |
| Cipla |
7.29 |
| Astrazeneca Phar |
6.20 |
| Indoco Remedies |
5.11 |
| SPARC |
4.98 |
| Dr Reddy's Labs |
4.96 |
| Abbott India |
4.82 |
| Glaxosmit Pharma |
4.69 |
| Biocon |
4.25 |
| Cadila Health. |
4.05 |
| Aurobindo Pharma |
2.98 |
| Zydus Wellness |
2.61 |
| Lupin |
2.46 |
| Fulford (India) |
2.25 |
| Ipca Labs. |
2.03 |
| Wyeth |
1.89 |
| Other Equities |
1.77 |
| Net CA & Others |
1.17 |
|
|
|
|
|
|
|
|
|